Pharmaceutical Commerce - January/February 2013

Hangzhou, Shanghai and Sydney bring 325,000 sq. ft. of dedicated space to market

PwC's annual analysis sees bright spots in R&D practices, while global economic troubles will constrain healthcare spending

Peer-reviewed study correlates adverse drug events (ADEs) with form of drug administration; can pharma manufacturers help?

Implementation of the Physicians Sunshine Act may require you to begin data gathering by Feb. 25, but questions remain over the law's details, from data to dollars

New report assesses the progress in adopting both of these marketing techniques

Patent-pending technology provides an 'e-fingerprint' to go with barcode data; data can be retrieved from a cloud-based repository

Next-gen SenseAware 2000 is deployed, along with a wider international distribution

When drugs in development today hit the marketplace in 2020, they will need evidence of economic and clinical value results to be commercially successful

Pharmaceutical marketing is now operating in a new landscape--the Economy of Attention

Abbott's spinout of AbbVie offers lessons

The 8,000th store opens in Los Angeles; landmarked bank building is a second Chicago flagship store

A new policy debate over drug regulation is emerging as the NECC scandal worsens

The looming California e-pedigree standards do not specify how to generate product codes, but random codes are easy to produce and essential for supply chain security

The Movianto acquisition presages a new era for the company

As the number of adverse events (AEs) grows year by year, regulators and industry managers are looking at automated systems to handle the burden

New study magnifies the lost opportunity for industry eighteen-fold; the global gap is $564 billion

HDMA's fourth edition polling its members and manufacturers, on trends in specialty distribution